ClinicalTrials.gg
RecruitingNCT05978206SARKOPENIAUpdated Apr 8, 2026

Study of the Effectiveness of Treatment of Sarcopenia With the Use of a Medicinal Product (Nandrolone), Comprehensive Physiotherapy and Diet

A Phase 2 interventional study of Nandrolone Decanoate and Physiotherapy Intervention in Sarcopenia, sponsored by National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland. Recruiting at 1 site in Poland. Open to participants aged 60 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
60 Years to 99 Years
Sex
All
01

Study summary

This is a single-center, prospective, randomized, double-blind (pharmacotherapy), placebo-controlled, and comprehensive physiotherapy and nutritional intervention phase II clinical trial to determine the usefulness of nandrolone decanoate in a new indication (sarcopenia).

Patients will be randomized 1:1 to receive nandrolone decanoate (50 mg intramuscular injection over four visits every 3 weeks) or placebo (1 ml volume equivalent to 50 mg intramuscular nandrolone decanoate dose) for 12 weeks (83-85 days ). Both groups will receive comprehensive physiotherapy and nutritional intervention.

There will be 5 outpatient visits to the research center. The procedures and assessments performed as part of the study are listed in the study schedule.

It is planned to include 168 patients in the study, which, assuming a 10% level of non-completion of the program, will result in the examination of 152 patients (76 in each arm). The study will cover people aged over 60 to 99 years of age with confirmed muscle weakness measured with a hand dynamometer (\< 27 kg for men and 16 kg for women) and with a decrease in: muscle mass of upper and lower limbs (ASMM) (7.0 kg/m2 height in men and 5.5 kg/m2 in women) or total muscle mass of the upper and lower extremities (\< 20 kg in men and \< 15 kg in women) by densitometry.

02

Conditions studied

  • Sarcopenia

Browse trials for

03

In context

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

This study's planned enrollment of 168 is above the median of 60 across 860 interventional studies indexed under Sarcopenia.

Browse Sarcopenia studies →

Lead sponsor

National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland is the lead sponsor of 10 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. individuals aged 60 years or older through 99 years of age.
  2. Patients meeting the following criteria diagnosed with sarcopenia based on EWGSOP 2 criteria from 2019:

    • weakness of muscle strength measured by hand dynamometer ( \< 27 kg for men and 16 kg for women) and
    • reduction in densitometry:

      • upper and lower limb muscle mass (ASMM)(below 7.0 kg/m2 height in men and 5.5 kg/m2 in women) or
      • total muscle mass of the arms and legs in men less than 20 kg and less than 15 kg in women).

Exclusion criteria

Exclusion Criteria:

  1. (MMSE) score less than 24;
  2. malignant neoplasm, lymphoproliferative or myeloproliferative disorders requiring oncologic or palliative treatment and the period before: 5 years in the case of: malignant melanoma, leukemia, Hodgkin's disease, malignant lymphomas, kidney tumors, 12 months in the case of other malignant neoplasms after the completion of surgery, chemotherapy or radiotherapy;
  3. history of oncologic diagnosis of focal lesions in the prostate gland;
  4. acute and chronic inflammatory diseases of the gastrointestinal tract that present with malabsorption (celiac disease, ulcerative colitis, Crohn's disease, etc.);
  5. uncompensated hyper- or hypothyroidism;
  6. recent history of myocardial infarction or stroke (up to 4 weeks prior to study entry); history of thromboembolism (up to 6 months prior to study entry) or recurrent thromboembolism;
  7. poorly controlled hypertension;
  8. liver impairment ( and/or ALT > 3x normal: AST> 111 U/l and ALT> 123 U/l); 9 Acute kidney injury and/or chronic kidney disease (stage G4 and G5);

10. nephrotic syndrome, acute or chronic glomerulonephritis; 11. advanced circulatory failure ( stages III and IV); 12. Acute and chronic respiratory failure requiring oxygen therapy; 13. Amyotrophic lateral sclerosis, multiple sclerosis, myasthenia gravis, dystrophies, spinal muscular atrophy type IV, primary muscular disorders (ICD-10 G71), toxic-field myopathies, myopathies in the course of infectious and parasitic diseases. Epilepsy; 14. need for treatment during the study period:

  • systemic for more than 3 weeks at a dose equivalent to greater than or equal to 5 mg prednisone;
  • hormone replacement therapy,
  • 5-alpha reductase inhibitors,
  • aromatase inhibitors,
  • anti-estrogenic hormonal drugs with anabolic effects other than nandrolone decanoate,
  • megestrol. 15. Lack of for participation in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
168 participants (estimated)

Study arms

  • Experimental
    Nandrolone

    Drug: Nandrolone Decanoate · Behavioral: Physiotherapy Intervention · Behavioral: Nutritional Intervention

  • Placebo comparator
    Placebo

    Behavioral: Physiotherapy Intervention · Behavioral: Nutritional Intervention · Drug: Placebo

Interventions

  • Patients will receive nandrolone decanoate (1 ml, 50 mg/ml intramuscularly given per visit) or placebo

  • BehavioralPhysiotherapy Intervention

    The physiotherapeutic intervention includes the following components: 1. Strength training will include strength exercises 3 x a week x 30 min - load from 60% to 80% 1RM for individual muscle groups, - 10 repetitions of the exercise, - 1-3 series in 1 session (break between sessions 60 seconds). 2. Endurance training will include aerobic exercises (cycle ergometer, treadmill, general fitness exercises) 3 times a week x 30 minutes, load from 60% to 80% of maximum heart rate.

  • BehavioralNutritional Intervention

    An individual diet in terms of calorific value and the content of energy substrates - proteins, fats and carbohydrates, as well as other nutrients, in accordance with specific nutrition standards.

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change in physical fitness as assessed by the SPPB test score

    Change in physical fitness as assessed by the SPPB test score (4- meter gait speed test version) in points, at the 5th study visit relative to the test score performed at visit 1

    Time frame: in the 12th week of the study

  2. Change in the 400-meter walk test score

    Change in the 400-meter walk test score in time units, at the 5th test visit, relative to the test score taken at visit 1

    Time frame: in the 12th week of the study

Secondary outcomes

  1. lower limb muscle strength

    lower limb muscle strength assessed with the result of the test of getting up 5 times from a chair per unit of time, upper limb muscle strength assessed with the result of the dynamometric handgrip test in kilograms during the 3rd and 5th visit of the examination in relation to the result made during the 1st visit

    Time frame: in the 6th and 12th week of the study

  2. Respiratory muscle strength

    Respiratory muscle strength assessed as a result of changes in airway pressures during inhalation and exhalation during the 5th visit of the study in relation to the result of the test performed at visit 1

    Time frame: in the 6th and 12th week of the study

  3. muscle mass

    muscle mass: assessed on the basis of the content of lean body mass of the upper and lower limbs in the study of body composition analysis using the electrical bioimpedance method; during the 3rd and 5th study visit in relation to the result of the study performed during visit 1

    Time frame: in the 6th and 12th week of the study

  4. muscle mass of the upper and lower limbs

    muscle mass of the upper and lower limbs: assessed on the basis of the content of lean body mass of the upper and lower limbs in the densitometry test during the 5th visit of the study in relation to the result of the test performed during visit 1

    Time frame: in the 6th and 12th week of the study

  5. score of the Sarc-QoL quality of life questionnaire (validated Polish version)

    score of the Sarc-QoL quality of life questionnaire (validated Polish version) during the 5th visit of the study in relation to the result of the study performed during visit 1

    Time frame: in the 6th and 12th week of the study

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Dec 2026, 40 months after the start.

Of 20 phase 2 interventional studies under Sarcopenia, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's planned 40 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2023
First posted
Aug 7, 2023
StartActual
Aug 10, 2023
Primary completionEst.
Dec 12, 2026
CompletionEst.
Dec 30, 2026
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05978206
Lead sponsor
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
Collaborators
Medical Research Agency, Poland
Responsible party
Sponsor
First posted
Aug 7, 2023
Start date
Aug 10, 2023
Primary completion
Dec 12, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Apr 8, 2026

Study contacts

Iwona Jannasz
Contact
iwona.jannasz@spartanska.pl
226709188 ext. +48
Tomasz Targowski, Prof. PhD, MD
principal investigator · National Institute of Geriatrics, Rheumatology and Rehabilitation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nandrolone Decanoate

Start the discussion